Article
Pharmacological reactivation of p53 as a strategy to treat cancer.
Journal of internal medicine - 1 Feb 2015
Zawacka-Pankau J, Selivanova G
Abstract excerpt
It has been confirmed through studies using the technique of unbiased sequencing that the TP53 tumour suppressor is the most frequently inactivated gene in cancer. This finding, together with results from earlier studies, provides compelling evidence for the idea that p53 ablation is required for the development and maintenance of tumours. Genetic reconstitution of the function of p53 leads to the suppression of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
